Powerheart G5 is first FDA-cleared AED to combine fully auto shock delivery, fast shock times and dual-language functionality
Opto Circuits (India) Group Company, Cardiac Science has unveiled its newest automated external defibrillator (AED) to the US and Canadian market representing a technological milestone in the AED industry and high anticipation from its loyal customers.
The Powerheart G5 is the first FDA-cleared AED to combine fully automatic shock delivery, dual-language functionality, variable escalating energy, and fast shock times to help save a sudden cardiac arrest(SCA) victim‘s life. SCA is the number one global cause of death with 17.3 million deaths each year, according to the American Heart Association.
“The North American AED market has yearned for an AED of this technology, scope, and importance,” said Vinod Ramnani, Chairman and MD, Opto Circuits (India) . “We have seen the impact of this product when we launched it in Europe back in 2012: immediate market share, adoption, and demand.”
Along with its sister AED, the Powerheart G3, the Powerheart G5 is designed to enable rescuers to swiftly provide effective, life-saving therapy to aid a person who has suffered SCA, a condition in which the heart suddenly stops beating due to irregularities in its electrical system.
“As more and more countries recognise the threat posed by SCA, legislation and public attitudes are steering buying decisions. This, in turn, has allowed our company to maintain price-points as customers want AEDs that our easy to use, ready for operation, and feature advanced technology,” added Ramnani.